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Abstract 
Background: Selective serotonin reuptake inhibitors (SSRIs) have been associated with 
depletion of serotonin in platelets, and risk of bleeding. Objective: The main objective 
is to report the cases of two young males with no medical problems other than their 
psychiatric disorders presenting with lower gastrointestinal bleeding after paroxetine 
use. Method: We report two cases of lower gastrointestinal bleeding in young, healthy 
subjects, after the use of low-medium doses of paroxetine. Results: The scarce 
literature available suggests that SSRIs in general, and paroxetine in particular, increase 
the risk of lower gastrointestinal bleeding. Conclusion: SSRIs have been associated 
with upper gastrointestinal bleeding but they also appear to be associated with lower 
gastrointestinal bleeding. Careful monitoring is particularly advisable during the initial 
period of use. Prospective studies are warranted to confirm the relationship between 
SSRI use and lower gastrointestinal bleeding. 
KEY WORDS: paroxetine, selective serotonin reuptake inhibitors, lower 
gastrointestinal bleeding 
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Paroxetine is a selective serotonin reuptake inhibitor (SSRI), and an effective long-term 
treatment for social anxiety and major depression.1 SSRIs in general, and paroxetine in 
particular, were described as associated with depletion of serotonin in platelets.2  
Serotonin is involved in platelet aggregation,1  and the association of bleeding to SSRI 
use was suggested two decades ago.3 In the last few years, some reviews have 
confirmed that initial fear.1, 4 In contrast with aspirin, SSRIs seem to be related to non-
ulcer, non-variceal gastrointestinal bleeds.5 SSRIs are usually associated with upper 
gastrointestinal bleeding but there is surprisingly little literature on lower 
gastrointestinal bleeding (LGIB) associated with SSRI use.1 The annual incidence of 
LGIB is approximately 20-30 cases per 100,000 inhabitants in Western countries; the 
incidence increases with age.6 We present two young males with no medical problems 
besides their psychiatric diagnoses presenting with LGIB after paroxetine use.  
Case reports 
Case 1. Mr. A is a 28-year-old Caucasian Dutch male who was treated for a panic 
disorder without agoraphobia with paroxetine titrated up to 40 mg/day. Five weeks after 
the onset of the paroxetine treatment and one week after the 40 mg/dose was reached, 
he presented with six episodes of sudden auto-limited LGIB, constipation and mild 
tremor. He was otherwise healthy, and used no medications or illegal drugs. As the 
patient did not relate paroxetine use with the LGIB episodes and did not see any 
physician at this time, he continued using paroxetine. Two weeks later, he underwent a 
series of routine haematological examinations after a consultation with his family 
doctor. All of them were normal and included: platelet count (306,000/mm3, normal 
laboratory range=130,000-400,000/mm3), the international normalized ratio (INR)=1 
and the remaining usual coagulation parameters; hemogram, iron, and ferritin; 
proteinogram, glucose, lipids, thyroid-stimulating hormone (TSH), thyroid hormones, 
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hepatic and renal parameters were also normal. A fecal occult blood test was negative. 
Visual inspection ruled out external hemorrhoids. Using anoscopy to rule out internal 
hemorrhoids was not considered because the patient lacked any risk factors and 
presented with no symptoms suggestive of them such as rectal pain, itching or 
hematochezia. The bleeding source was not identified. The paroxetine dosage was 
decreased to 20 mg/day and combined with 15 mg/day of mirtazapine with full 
remission of his symptoms after psychiatric consultation. After a one-year follow-up the 
patient did not report any further bleeding episodes.  
Case 2. Mr. B is a 20-year-old Spanish Caucasian male who was treated for a mild to 
moderate major depressive disorder, single episode, with paroxetine titrated up to 20 
mg/day. Besides the depressive episode, he was healthy, and was taking no medications 
or illegal drugs. Two weeks after starting paroxetine use and five days after reaching the 
20 mg/day dose, he developed mild tremor and headache, and an episode of moderate 
LGIB. He underwent a series of routine hematological examinations in the emergency 
department. All routine hematological examinations including platelet count were 
normal (298,000/mm3 x 109/liter; normal laboratory range=120,000-450,000/mm3). 
However, the activated partial thromboplastin time (40.23 seconds; reference laboratory 
range=22.5-38.0 seconds), and INR (1.28; reference laboratory range = 0.71-1.20) were 
slightly elevated. Lupus anticoagulant testing was negative. Visual inspection and 
anoscopy ruled out external and internal hemorrhoids, respectively. No bleeding source 
was identified. As the patient did not attribute the LGIB to the paroxetine use, he 
decided on his own to continue using paroxetine in the same dose of 20mg/d. He only 
disclosed the LGIB episode to his psychiatrist several months after the episode. He 
presented no further episodes of bleeding in the year following the LGIB episode.  
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Discussion 
Both patients were young, medically healthy subjects in monotherapy with paroxetine 
and other potential causes of bleeding, including hemorrhoidal bleeding, were excluded. 
The close temporal relationship between paroxetine use and LGIB suggested that the 
bleeding was possibly secondary to the use of paroxetine. Although an etiological 
relationship between paroxetine use and LGIB cannot be drawn from either case, the 
Naranjo probability scale7 score was 7 in both patients, suggesting a probable 
relationship between the LGIB and paroxetine use.  
 Our case reports are interesting for at least two reasons. First, because they give 
further support to a putative relationship between SSRI use and LGIB. Recent studies 
have confirmed previous safety concerns about the increased risk of bleeding, 
particularly in the upper gastrointestinal tract, among SSRI users1, 8 with a range of 
1/100 to 1/1000 patients/year of exposure among SSRI users.4 A recent report has also 
suggested an increased risk of LGIB among SSRI users.9 Unfortunately, there is little 
literature available on the relationship between SSRIs and LGIB, and the few available 
studies are retrospective.5, 9 Second, the clinical data here reported provide interesting 
insights about the relationship between paroxetine use and bleeding. Thus, both patients 
presented the LGIB episodes using low-medium paroxetine doses, during the initial 
months of paroxetine use, and neither of them presented with any further bleeding 
episodes in the year following the initial bleeding episode, despite the fact that both 
continued using paroxetine. It is important to remember that neither dose nor duration 
of SSRI use has been associated with bleeding risk.4 SSRIs inhibit the uptake of 
serotonin by platelets, and impair platelet aggregation and hemostasis. Even low-
medium doses of SSRIs can reduce serotonin content in more than 80% of subjects.10 In 
a 2-week randomized double-blind placebo-controlled study in healthy male volunteers 
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receiving paroxetine (20 mg/day), there was an important (83%) decrease in 
intraplatelet serotonin concentrations, reduced platelet plug formation, and prolongation 
of closure time.11 In another study with nineteen drug-free psychiatric outpatients 
initially tested before and after six weeks of paroxetine use, and also after a further 
increase to 40-50 mg day based on clinical symptoms for six more weeks, paroxetine 
maximally impaired platelet function at 20 mg day. Dose escalation to 40-50 mg day 
did not further influence hemostasis parameters.12 Interestingly, the mechanisms 
underlying the increased risk of bleeding among SSRI users seem to be the same ones 
that yield a protective effect against ischemic heart disease.1 Furthermore, platelet 
serotonin reduction is maximum in the first four to six weeks of treatment,13 which 
strongly suggests that the initial months of SSRI use comprise a period of higher risk of 
bleeding. Our cases occurred in weeks 5 and 2 after paroxetine onset. In our second 
case, there is no way of knowing whether the mild alterations in coagulation tests were 
an incidental finding or secondary to paroxetine use. Unfortunately, no baseline 
coagulation tests were completed before paroxetine was started, and bleeding time was 
not performed in either case.  
 As might be expected, the most frequent hemostatic abnormalities associated 
with SSRI use are decreased platelet activity and aggregability, and prolonged bleeding 
time.14 Paroxetine, fluoxetine, and sertraline, the SSRIs with highest degree of serotonin 
reuptake inhibition, are those antidepressants more frequently associated with 
modifications of hemostatic markers and abnormal bleeding.14 Interestingly, in the 
abovementioned study with 19 psychiatric outpatients on paroxetine treatment, the 
serotonin transporter gene (SCLC6A4) promoter polymorphism (5-HTTLPR) 
influenced the dose-response paroxetine effects on platelet function.12 Patients with the 
S’/S’ polymorphism displayed the largest hemostatic abnormalities, such as increased 
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closure time. However, in a prospective study conducted among 43 patients aged 18 to 
70 years old on paroxetine therapy, serotonin transporter polymorphisms did not 
influence bleeding time during SSRI therapy.15 More evidence is clearly needed.  
 This article has limitations. First, the patients did not attribute LGIB to the use of 
paroxetine and continued using it.  In the first patient, the psychiatrist saw the patient 
two weeks after the LGIB episode and recommended halving the dose. In the second 
patient, the psychiatrist recommended no changes because the patient disclosed the 
LGIB episodes several months after its occurrence. Ideally, patients should report 
adverse drug reactions (ADRs) at the time of its occurrence. Instead, the reality is that 
both health care professionals and patient underreport ADR.16, 17 The systematic use of 
ADR may be a solution; but as gastrointestinal bleeding is an infrequent ADRs of 
psychotropic use, it is not included in some ADR scales.18 Second, estimating the 
severity of blood loss is a complicated issue. The cases reported here were classified as 
mild and moderate LGIB episodes. Unfortunately, laypersons are usually inaccurate 
when visually estimating blood loss; so are medical students, nurses and experienced 
physicians.19 Physicians should place enhanced attention on the clinical assessment (e.g. 
pulse, skin color, blood pressure) or even laboratory analysis.19 Finally, the bleeding 
source was not identified in either case, but hemorrhoids were ruled out as a cause of 
the LGIB episodes in both. Consequently, bleeding episodes were considered 
idiosyncratic at the time of evaluation. Unfortunately, bleeding time was not performed 
in either case at the LGIB time. An abnormal bleeding time suggesting a platelet 
abnormality would have helped to establish a causal relationship between paroxetine 
use and LGIB episodes.  
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Conclusion 
These cases demonstrate that, even if SSRIs are efficient, well-tolerated antidepressants, 
with putatively protective effects (e.g., from ischemic heart disease), clinicians should 
also be aware of the potentially lethal bleeding risk. Therefore, aged people; the 
concomitant use of any drug, particularly non-steroidal anti-inflammatory drugs 
(NSAIDs) and aspirin; and/or any medical condition that could even further increase the 
bleeding risk, should be a matter of concern for clinicians. For instance, valproate 
treatment is frequently associated with thrombocytopenia, and occasionally has been 
associated with disturbances in coagulation.20 Thus, it is possible that the combination 
of valproate with SSRIs may increase bleeding risks, but this has not been studied as far 
as we know. To definitively establish the association between LGIB and SSRIs, larger 
studies with a prospective design are needed. Until these studies are completed it seems 
safer for clinicians and patients to be aware that increased risk for hemorrhagic 
complications during SSRI treatment may include LGIB too. Warning patients about 
the low risk of bleeding may be advisable during the initial period of SSRI use.  
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